All Industries

Copper Property CTL Pass Through Trust Schedules Live Call to Discuss Recent Financial and Operating Results

Copper Property CTL Pass Through Trust

Copper Property CTL Pass Through Trust (“the Trust”) announced today that it will host a live conference call on Tuesday, November 12, 2024 at 12:00 pm Eastern Time. Members of the Trust’s management team will discuss its recent financial and operating results as reflected in the Trust’s monthly report for the period ended October 31, 2024, and Form 10-Q for the period ended September 30, 2024, both of which are expected to be filed prior to the call. The conference call will include a question and answer (Q&A) session. Conference Call Details: DATE: Tuesday, November 12, 2024 TIME: 11:00 am CDT | 12:00 pm EDT DIAL-IN: U.S. & Canada Toll Free: (877) 841-2983 or International (215) 268-9893 WEBCAST: www.ctltrust.net via the Investor Relations Section or click here to access REPLAY (Available for 30 days): U.S. & Canada Toll Free: (877) 660-6853 / International: (201) 612-7415 Conference ID#: 13750090 Telephone Replays will be made available approximately 3 hours after the conference end time. Participants will be required to state their name and company upon accessing the replay. Additional information, including the Trust’s Monthly and Quarterly Reports, as well as other filings with the Securities and Exchange Commission (“SEC”) can be accessed via the Trust’s website at www.ctltrust.net. About Copper Property CTL Pass Through Trust Copper Property CTL Pass Through Trust (the “Trust”) was established to acquire 160 retail properties and 6 warehouse distribution centers (the “Properties”) from J.C. Penney as part of its Chapter 11 plan of reorganization. The Trust’s operations consist solely of owning, leasing and selling the Properties. The Trust’s objective is to sell the Properties to third-party purchasers as promptly as practicable. The Trustee of the trust is GLAS Trust Company LLC. The Trust is externally managed by an affiliate of Hilco Real Estate LLC. The Trust is intended to be treated, for tax purposes, as a liquidating trust within the meaning of United States Treasury Regulation Section 301.7701-4(d). For more information, please visit https://www.ctltrust.net/. Forward Looking Statement This news release contains certain “forward-looking statements”. All statements other than statements of historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “our vision,” “plan,” “potential,” “preliminary,” “predict,” “should,” “will,” or “would” or the negative thereof or other variations thereof or comparable terminology and include, but are not limited to, the Trust’s expectations or beliefs concerning future events and stock price performance. The Trust has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Trust believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. These factors, including those discussed in the Trust’s Registration Statement on Form 10 filed with the Securities and Exchange Commission (the “SEC”), may cause its actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. For a further list and description of such risks and uncertainties, please refer to the Trust’s filings with the SEC that are available at www.sec.gov. The Trust cautions you that the list of important factors included in the Trust’s SEC filings may not contain all of the material factors that are important to you. In addition, in light of these risks and uncertainties, the matters referred to in the forward-looking statements contained in this news release may not in fact occur. The Trust undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. Contact Details Jessica Cummins +1 847-313-4755 jcummins@hilcoglobal.com Company Website https://ctltrust.net/about/default.aspx

November 05, 2024 01:46 PM Eastern Standard Time

News Release

The Money Service Lab announces the launch of its licenced service model for Issuers globally

BNP Paribas SA

The Money Service Lab (MSL) today announced the launch of its licencing model for entities wishing to become their own issuing processor for Visa, MasterCard, Discover and other card scheme networks. The move comes after the company successfully completed its MasterCard Europe certification, alongside Visa LAC and other ongoing certifications. Europe alone has circa 5,000 banks in situ and globally the number is closer to 40,000 whilst there are less than 50 processors operating at any scale. The European Central Bank estimated that there were over 72 billion card transactions processed in Europe in 2023. Lee Britton, Strategy Director at MSL said “When we founded the Money Service Lab in 2021 our vision was based on 2 factors; a huge increase in card-based transactions, whether physical or digital and a gap in the market for banks and issuers to become their own processor, instead of relying on the old incumbents. We set about creating a platform that could cater for three scenarios, the first being the old established ‘Managed Processing as a service’, where MSL would run the platform on behalf of our clients and do everything, from soup to nuts. The second scenario we envisaged was where MSL would still be the certified processor but our clients would run the platform on a day-to-day basis, configuring programmes, changes, fees, limits, spend control functions and multi-currency capabilities for example. But the third scenario we planned for and built, and the one that really interested us the most, was where we could licence or sell the platform to banks, credit card issuers, eMoney institutions, tech companies and integrators, where they would become the certified processor in their own right with access to the source code and ability to customise and change as they wished”. Mike Muscato, CTO for Money Service Lab, stated “What intrigued us at the beginning of the journey was ‘how do we empower more banks and issuers generally to take control of the card systems they rely on and enable them to launch portfolios on their own version of the platform’. We knew it would be a challenge and we had a lot of head-scratching moments in 2022 to figure out how to create multiple instances of the platform, almost at the drop of a hat and to maintain all the functionality available in our platform consistently through our licencing model, without compromising on our enormous processing power and ability to throttle and process circa 9000 Transactions Per Second (9000 TPS). Luckily, we had huge experience of this in our sister company, Muscato Corporation where we licence our switch, ENGIN© to many of the world’s largest processors, in Healthcare and Financial systems as examples. We estimate that around 15% of all financial transactions in the USA pass through ENGIN© through our licence customers, so it was a no-brainer for us at MSL to put ENGIN© at the heart of our platform” Mike Muscato went on to say “So as we perfected the MSL platform we took a leaf out of the Muscato Corporation playbook and took the same licencing approach, so if you are licencing the MSL platform you are getting also the best of the ENGIN© switch as well, tried and tested by some of the world’s largest financial processors. Conor Doyle, CEO of MSL, said ‘With card-based transactions increasing year-on-year at around 15% it is a clearly a fast-growing market, accelerating at a rapid pace. Our belief is that there are too few processors and globally there are just a handful present in every region, mostly managing legacy technical stacks. That gap in the market is where a company like MSL can make a difference. Multi-Currency processing is standard for us, alongside spend controls, fraud and risk monitoring and our pretty much unique ‘Compliance as a Service’ risk and AML system which provides the issuer or technology partner with everything needed to be able to control and report suspicious activity to their own regulator, as well as complementing their own internal systems. My belief, having been around processors since the early 2000’s, is that we have built something that we can grow globally but we can put the power back into the hands of the banks, credit card issuers and eMoney and Payment Institutions, so that they can process their own cards at a fraction of the cost they pay externally today. Combine that with the ability to move between any one of the three model (managed, hybrid or licenced) as well as the fact we are more than happy to sell the platform as an instance and pass over the source code, makes it, in my view, a pretty compelling proposition’. About MSL Payments Headquartered in London, United Kingdom, with offices in USA and Spain, MSL provides an innovative payment solutions platform for banks, credit card issuers, eMoney and Payment Institutions and programmes and programme managers. Currently already certified in Europe and Latin America Caribbean, MSL will continue to obtain certifications globally to help businesses all over the world create awesome customer experiences. MSL offers a full range of services, including issuing processing either as managed service or as a licence (where the client becomes the processor) as well as market-leading programme management and highly skilled payments expertise to create customisable feature-rich solutions for issuers, businesses, brands and their customers. About Muscato Corporation Specializing in developing, marketing and implementing transaction technologies for both established and emerging markets and creating outlets for licensing and operating its solution sets. Muscato has a firmed foundation in several vertical markets, including healthcare and financial payments, with significant financial and operational impact to the overall organization. With over 35 year track record of architecting, developing and implementing highly scalable transaction processing software, managing tens of billions of transactions yearly, Muscato is widely recognized in performance engineering and delivery systems. Muscato has a worldwide footprint through our suite of products. Products define the next generation of e-commerce platforms, specifically message brokering, card management, fully integrated healthcare payer exchange, money remittance, mobile banking, and transaction security. For MSL Payments Come and explore the many opportunities our platform has to offer by visiting us at www.themsl.com or email us on info@themsl.com For Muscato Corporation For all enquiries, please reach out to Muscato Corporation at sales@muscato.com or visit us at www.muscato.com/ News Source: PinionNewswire Contact Details Muscato Corporation sales@muscato.com Company Website https://csj-consulting.com/

November 05, 2024 09:01 AM Eastern Standard Time

With Milei's Economic Reforms, Gaucho Holdings Eyes Growth In Argentina's Markets

Benzinga

By Anthony Termini, Benzinga In December 2023, Argentina elected Javier Milei to the presidency after he pledged fiscal balance, zero budget deficits, and pro-market reforms. Almost a year into his term, the impact is starting to become evident. The World Bank says his policies will likely bring in some “$10 billion in net international reserves by the end of 2024.” Investors have taken notice. The Global X MSCI Argentina ETF (ARCA: ARGT) is up about 44% since Milei took office. Milei’s policies have helped to make him quite popular, and executives at Gaucho Group Holdings, Inc. (NASDAQ: VINO) believe all of this could increase opportunities for investors seeking to participate in the country’s expected growth. Gaucho Group Holdings Expanding In Argentina Gaucho Holdings is a diversified real estate and luxury brand holding company with assets in hospitality, wine making and fashion. The company also operates a growing collection of e-commerce platforms focused on fine wines, luxury real estate and leather goods and accessories. In May, Gaucho Holdings announced a new mortgage lending division intended to serve as the company’s self-financing option for buyers of its luxury vineyard real estate project, Algodon Wine Estates. Gaucho Holdings says it plans to expand the unit beyond its own properties in a move targeted to benefit from the Argentine government’s recent tax amnesty program. The program seeks to repatriate some $204 billion in untaxed wealth held by Argentinians outside the country. The company believes the tax amnesty measures could create an improved investment environment and a revival in mortgage lending. It says it believes the move could invite heightened confidence among Argentine citizens and the global investment community. The company argues that the Argentine real estate market is “now more promising than ever, as real estate values across the country reflect growing stability and demand.” Argentina’s Economic Landscape Is Evolving For many analysts, Argentina appears to be entering a new era of optimism. In his 2025 draft budget proposal, Milei estimates that his administration’s economic reforms will expand the economy by 5% in 2025. Banco Bilbao Vizcaya Argentaria (BBVA) (NYSE: BBVA) expects a 6% rebound in 2025. BBVA also expects the country’s GDP to grow by 4.5% in 2026 and to see inflation decline by nearly 38%. Since Milei became president, monthly inflation has dropped rapidly and recently hit a 31-month low, Gaucho Holdings reports. According to Doug Casey, a leading advisor to Gaucho Holdings, “If Milei’s reforms stick, within a decade, Argentina could become the most prosperous country in the world.” He attributes this to what he says is Argentina’s potential for substantial economic renewal, which he says has set the foundation for long-term growth and increasing the appeal for business travel and investment. In October, the World Bank announced over $2 billion in new loans to Argentina. About the same time, Argentina’s Central Bank said that it was working with banks and credit card companies to enable debit cards denominated in U.S. dollars. The move is part of the government’s push to adopt the U.S. dollar as Argentina’s official currency. Also in October, the Inter-American Development Bank (IDB) announced that it would grant $3.8 billion in aid to the country to be used for both public and private sector projects. Ilan Goldfajn, president of the IDB said that Milei’s reforms had “achieved remarkable progress in restoring much needed fiscal balance” to Argentina’s economy. Milei announced the country’s first quarterly budget surplus in 16 years in April. The changing economic landscape has prompted Argentina’s leading private bank, Grupo Financiero Galicia, to foresee a surge in lending. It expects new business and consumer loans to make up 40% of its total assets by the end of this year. Economic Reforms May Benefit Gaucho Holdings One possible sign that President Milei’s reforms are reshaping Argentina’s economy is that rental supply in Buenos Aires has surged since deregulation. And Gaucho Holdings says the promising signs of sustainable growth like this align with its strategic vision. The company believes such reforms may help reinforce its position across luxury real estate, hospitality, and fashion markets – each of which it expects to benefit from what it calls Argentina’s economic revival. Gaucho Holdings says that it is establishing itself as the “premier vehicle for investment in Argentina.” The company’s recent announcement said it is creating “a distinctive gateway for global investors who seek to participate in and benefit from Argentina's economic resurgence.” The company notes that its assets are strategically aligned with the country's “advancing market dynamics.” For Gaucho Holdings, capital infusions from the World Bank and the IDB enhance Argentina’s investment landscape and support the company’s growth initiatives in real estate, wine and luxury markets. It notes that stability attracts global interest. The company also says that deregulated markets enhance investment opportunities, and that the latest reforms facilitate smoother transactions and “enhance investor confidence.” The revival in consumer credit and home financing strengthens the market outlook, which could support Gaucho Holdings’ initiatives in real estate and position it to benefit from Argentina’s strengthened economic landscape, the company argues. It points out that real estate values in Argentina’s prime wine regions continue to offer substantial discounts per square foot compared to the world’s leading wine centers. Gaucho Holdings believes this presents an “unmatched opportunity” for growth. To align its commitment to promote Argentina’s growth and to connect with international investors, Gaucho Holdings recently hosted an exclusive wine tasting event in partnership with the Argentine Consulate in New York City. The event featured the latest releases of Malbec varietals from Algodon Fine Wines and was a platform for discussions about Argentina’s economic potential and the avenues for growth that international investment can support. Featured photo of Algodon Wine Estates in San Rafael, Mendoza, Argentina, courtesy of Gaucho Group Holdings, Inc. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 05, 2024 08:35 AM Eastern Standard Time

Image

SBC Medical Group (Nasdaq: SBC) CEO: "If We Become No. 1 In Asia, I Believe We Will Become No. 1 In The World"

Benzinga

By Gerelyn Terzo, Benzinga In what social media has declared the “undetectable era” of cosmetic surgery, beauty treatments have never been so appealing. As celebrities such as Christina Aguilera remain transparent about their cosmetic treatments while continuing to turn back the clock on their natural appearance, some experts say any stigma that was once associated with plastic surgery has disappeared. One leader from Asia now making its mark in the industry globally is SBC Medical Group Holdings (NASDAQ: SBC), a Tokyo-based medical company providing franchise services to aesthetic medical clinics and improving the lives of people around the world. In a recently aired webcast, SBC Medical CEO Yoshiyuki Aikawa shared his vision for the future of his growing company while also highlighting investment opportunities now that the stock is trading on the Nasdaq. He also explained that while the company has come so far, there is still more work to be done. Wall Street also seems to have paid attention. In a report released on Oct. 23, Zacks Small-Cap Research placed a $15.40 price target on SBC shares, suggesting the stock has room to almost double in price from its price of $7.23 at the time of the report’s publication. Zacks analyst M. Marin shared her insight on SBC’s franchise model as the company continues to expand its global footprint both organically and through M&A. Investors who are inclined to share in this bullish outlook can keep track of the company’s latest developments here. SBC Medical’s Growth Strategy While SBC Medical only recently became a publicly traded company, it’s been around for over two decades, getting its start as Shonan Beauty Clinic (SBC) in Japan’s Fujisawa city. Fast-forward, and SBC has evolved into a medical provider powerhouse, boasting the biggest network of franchised clinics in Japan and leading the country’s aesthetic medical industry as the Asia population boom continues to unfold. SBC Medical reports that it oversees 220 clinics, including Shoan Beauty clinics, and is growing, reaching close to 4 million customers each year – 70% of whom are repeat patients. Additionally, SBC Medical is in the early stages of international expansion, with clinics located in Los Angeles, CA. and Ho Chi Minh City, Vietnam. With its sights set on further expansion into adjacent fields, including B2B partnerships, SBC Medical, in many ways, is just getting started. “If we become No. 1 in Asia, I believe we will become No. 1 in the world,” said Mr. Aikawa. Chief among the services SBC Medical provides to aesthetic clinics are marketing services, but SBC also supports them in other ways such as recruitment, training, evaluations, medical equipment and expertise. Mr. Aikawa expects these facilities will serve as a springboard to debut additional clinics in these jurisdictions. SBC Medical’s management team represents nearly 25 years of experience in this industry, setting itself apart from the pack with features like a fully digitized integrated system and simplifying things for medical professionals. Its approach seems to be working, as SBC Medical reports that it holds the largest piece of the market share pie in Japan’s medical aesthetic sector, controlling close to one-third of the nation’s growing aesthetic medical segment and further solidifying its leadership position as a franchisor. SBC Medical’s Balance Sheet Mr. Aikawa, who has long been impressed by the effectiveness of aesthetic medicine, pointed to SBC Medical’s solid fundamentals on the balance sheet – the company is generating rising revenue that reached $194 million as of FY2023, coupled with an attractive profit margin. Its diversified portfolio also extends to other self-pay medical treatment areas such as fertility, orthopedic, regenerative medicine and laser eyecare, all of which appeal to many investors. Here’s a snapshot of the company’s financial strength: Revenue YoY Grow: A five-year compound annual growth rate (CAGR) of 24% Gross Profit Margin: 71%-plus Operating Profit Margin: 26%-plus Mr. Aikawa – a visionary whose passion for this business has proven unwavering – has made it his mission for SBC Medical to win. He prioritizes cash on the balance sheet that can be used for growth activities such as M&A. This stable balance sheet would also provide assurance for the sensitive needs of the medical practices that SBC supports. He also has strong hopes for the company’s convenient, trustworthy and efficient online clinical services, including services like AI med provided by the group company, the performance of which has been growing annually. Japan’s Aesthetic Medical Market Growth Potential Japan is a major focus area for SBC Medical, considering only 10% of the country’s population currently seeks aesthetic medical treatments, a low base with enormous potential. Mr. Aikawa expects that segment to at least double to 20% to be closer in line with South Korea’s population turning to cosmetic surgery, owing in part to the advertising campaigns of the Shonan Beauty Clinic. Market penetration among Japan’s core customer group – women up to their 30s – is growing. However, the sweet spot for SBC Medical here is both middle-aged male and female markets, as SBC Medical pursues affordable price points that will make monthly clinic visits possible. “I feel like we are only halfway through achieving that goal, so we should work even harder,” said Mr. Aikawa, pointing out that the number of customers aged 40 is increasing. As SBC Medical continues to expand its clinical base and improve the lives of people around the world, interested investors have an opportunity to participate in its growth story. Zacks’ analyst research suggests SBC Medical has the wind at its back, particularly owing to an increasingly popular aesthetics medicine market in Japan. Investors can learn more about SBC Medical’s stock and fundamentals here. Featured photo by Alexas_Fotos on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 05, 2024 08:30 AM Eastern Standard Time

Image

News Release

Building Momentum: Zynex Inc.’s (NASDAQ: ZYXI) Steady Rise in the Pain Management Market

ZYXI

Demand for pain management devices is climbing worldwide, fueled by several major trends. As chronic disease rates soar, the need for effective, drug-free pain solutions has grown more pressing. At the same time, advancements in medical tech have opened doors to safer, non-invasive pain relief options, making them more widely adopted by healthcare providers. Rising numbers of surgeries have also created a strong demand for post-operative pain control, while the pain monitoring market continues to surge. With these combined factors, the global pain management device market is expected to reach $5.68 billion by 2032, expanding at a steady 9% CAGR. In this dynamic and fast-evolving field, Zynex Inc. (NASDAQ: ZYXI) stands out as a key player, bringing new solutions to the growing pain management market. A Closer Look at a Leading Innovator in Pain Management Founded in 1996, Zynex Inc. has carved out a unique space in the medical technology industry, specializing in non-invasive medical devices designed for pain management and rehabilitation. With a mission to improve the lives of patients with chronic pain and other debilitating conditions, Zynex consistently develops innovative solutions that support pain management without relying on medications. The recent FDA approval of its latest device, the TensWave, and strong financial performance through Q3 2024 highlight Zynex’s upward trajectory in a growing market. Expanding Product Line with FDA-Cleared TensWave Device Zynex's newest offering, the TensWave device, received FDA clearance in September 2024. This device is a non-invasive pain relief option that uses TENS (Transcutaneous Electrical Nerve Stimulation) technology, a proven method to alleviate pain without medication. According to CEO Thomas Sandgaard, TensWave was developed to meet the demand for a high-quality TENS device that fits insurance reimbursement criteria. "We recognized a gap in the market," Sandgaard said, "and TensWave is our answer to that demand. It complements our flagship device, the NexWave, by giving patients a safe, effective, and drug-free alternative for pain relief." The TensWave device is designed to work in tandem with Zynex’s other products, specifically the NexWave, which offers multiple electrotherapy modalities. While NexWave remains Zynex’s top-tier product, TensWave offers a more targeted solution for patients covered under insurance plans that only reimburse TENS-based treatments. By diversifying its product lineup, Zynex positions itself to cater to a broader range of insurance plans, potentially reaching more patients who need accessible and effective pain management tools. Strong Financial Performance and Business Growth Zynex’s Q3 2024 financial results showcase the company’s resilience and growth momentum. During the quarter, orders in the Pain Management division saw a 13% increase compared to the same period in 2023, while revenue per sales representative jumped by 25%, reaching approximately $530,000. Overall, Zynex reported net revenue of $50 million, a slight increase from the previous year, and net income of $2.4 million, equating to an EPS of $0.07. Cash flow from operations was robust at $7.1 million, and the company’s working capital stood at $58.5 million as of September 30, 2024. In February 2022, an article from Seeking Alpha suggested that Zynex might face a 50% drop in EBITDA due to contract changes with UnitedHealthcare. However, rather than the anticipated loss, Zynex managed to maintain and even grow its partnership with UnitedHealthcare. Over the past three years, Zynex has consistently added new patients with UnitedHealthcare, backed by a renewed agreement with the insurer. Notably, Zynex has recorded steady revenue growth, with year-over-year increases of 21%, 17%, and 9% since 2022, effectively countering these earlier predictions and showcasing Zynex’s operational strength. Looking ahead to Q4, Zynex has set a revenue target of $53.6 million with an estimated EPS of $0.09. For the full year of 2024, the company expects to achieve net revenue of at least $200 million, representing a 9% growth from the prior year and an EPS of $0.20. These projections suggest that Zynex is on track to sustain its current pace of expansion. Strategic Focus on Innovation and Market Adaptability One of Zynex’s core strengths lies in its ongoing commitment to research and development, aiming to diversify its product portfolio to address unmet needs in pain management. Sandgaard has emphasized that Zynex’s long-term goals include not just incremental growth in its pain management division but also the expansion of its orthopedic products, ensuring that the company has a well-rounded suite of medical devices. In the words of Sandgaard, “We are working to expedite the onboarding of new sales reps while maintaining a high standard for productivity. Our focus on FDA approvals of next-generation devices and new therapy products delivered FDA clearance of our new TensWave device during the quarter.” Alongside pain management, Zynex is making strides in non-invasive monitoring systems for hospital use, indicating that the company is serious about diversifying beyond its core offerings. This multi-pronged approach gives Zynex the flexibility to adjust to changing market demands while further establishing its reputation as a provider of comprehensive, non-invasive healthcare solutions. Future Growth Potential With the FDA approval of the TensWave device, Zynex has reinforced its presence in the pain management market, where demand for non-opioid treatment options is on the rise. The device could become a significant revenue driver, particularly as the opioid crisis has heightened interest in alternative pain management therapies. TENS therapy, a proven method for reducing both chronic and acute pain, positions Zynex favorably among patients and healthcare providers looking for safe, effective treatments. Zynex’s current product line also includes devices for cold and hot therapy, cervical traction, braces, and compression solutions, allowing it to cater to a broad array of patient needs. As the company anticipates a return to its typical growth rate of approximately 20% in the pain management division in 2025, the new products and strong sales infrastructure could enable it to scale more effectively. Conclusion In 2024, Zynex Inc. (NASDAQ: ZYXI) has shown resilience by expanding its product portfolio and maintaining steady growth. The FDA clearance of the TensWave device further strengthens its position in the non-invasive pain management field, supporting its mission to deliver effective, drug-free pain solutions. With solid revenue growth and strong partnerships, ZYXI is set to build on its progress, providing lasting value for patients and shareholders alike. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

November 05, 2024 07:00 AM Eastern Standard Time

The Trading Pit Elevates Trader Experience with NinjaTrader Integration for Prime Futures

The Trading Pit

By The Trading Pit • The Trading Pit integrates the award-winning NinjaTrader platform into its Prime Futures Challenges, responding directly to trader demand. • This collaboration enhances the trading experience by offering cutting-edge tools that provide precision, efficiency, and control to funded futures traders. • With the NinjaTrader integration, The Trading Pit is expanding its global reach into key markets, including the UK, Canada, and the US Liechtenstein, November 4th, 2024 – The Trading Pit, a leading proprietary trading firm, announces the integration of the renowned NinjaTrader platform into its Prime Futures Challenges, alongside the advanced capabilities of Tradovate and TradingView. This strategic move reinforces The Trading Pit’s commitment to elevating the trading experience by providing traders with a comprehensive suite of cutting-edge tools. Responding to Trader Feedback Traders have shown great enthusiasm for the NinjaTrader platform, renowned for its speed, efficiency, and customizable features. At The Trading Pit, we’ve always prioritized listening to our community, and this integration is a clear reflection of that commitment. By offering NinjaTrader with its Prime Futures Challenges, The Trading Pit provides prop traders with the precision and control needed to excel in the competitive futures market. A New Era of Trading with NinjaTrader NinjaTrader's advanced functionalities allow futures traders to execute strategies with unmatched accuracy, tailor their trading environment to individual preferences, and gain deeper insights into market movements. Combined with Tradovate's commission-free futures trading and TradingView's powerful charting and analysis tools, this partnership marks the beginning of a new chapter for The Trading Pit, where innovation seamlessly blends with trader-focused solutions. "In addition to NinjaTrader, traders will enjoy seamless access to the Tradovate Trading platform, all with the same user account," added Daniela Egli, CEO of The Trading Pit. "We are also pleased to offer the TradingView add-on for free to all our customers, enhancing their analytical capabilities at no extra cost." Expanding Opportunities This integration is particularly significant as The Trading Pit seeks to expand into new markets, including the UK, Canada, and the US, where NinjaTrader enjoys a strong following. The collaboration aims to attract futures traders and members of the NinjaTrader community, offering them an enhanced trading experience and funded accounts. About The Trading Pit The Trading Pit, headquartered in Liechtenstein with offices in Spain and Cyprus, is an award winning proprietary trading firm redefining modern trading opportunities. By offering traders the chance to hone their skills on cutting-edge simulated platforms, the firm empowers them to enhance their strategies while earning up to 80% of their simulated profits. The Trading Pit’s diverse range of trading challenges is meticulously crafted to identify and cultivate trading talent, with comprehensive support from an array of educational resources, mentorship, and personalized tools. For more information visit www.thetradingpit.com. Contact Details Nuria Medrano - Head of Marketing nmedrano@thetradingpit.com Company Website https://www.thetradingpit.com/

November 04, 2024 11:00 AM Eastern Standard Time

Market Alert: New Report Highlights Steakholder Foods Major Shift to Commercialization & Revenue Generation

Global Markets News

A new report by PESG Research highlights Steakholder Foods’ (NASDAQ: STKH) transformative journey from research and development to commercialization in the alternative protein and 3D food printing sectors. The report highlights how 2024 marked a pivotal year for the company, with strategic partnerships fueling revenue generation and positioning Steakholder Foods for potential growth in a booming market. Strategic Partnerships Lay Foundation for Revenue Growth Steakholder Foods secured multiple strategic agreements in 2024 that validate its proprietary technology and solidify its commercial potential. Key partnerships include a commercial memorandum of understanding with Wyler Farm, which involves the purchase of Steakholder Foods’ MX200 meat printer and SH™-Beef premix blends. This agreement also encompasses royalties and raw materials supply, enabling large-scale production of alternative proteins. Additional partnerships with the Industrial Technology Research Institute (ITRI) in Taiwan and regional collaborations in the Gulf Cooperation Council (GCC) highlight the company’s international reach. The GCC partnership, aimed at supporting local food security initiatives, involves constructing a pilot facility for hybrid-cultivated fish production and showcases Steakholder Foods’ scalability in new markets. These agreements are seen as significant steps toward establishing long-term, recurring revenue streams. Initial Purchase Orders Signal Commercial Viability According to the company, initial purchase orders from key partners such as Bondor Foods and Wyler Farm have initiated revenue streams, providing critical proof of concept for Steakholder Foods’ business model. In September 2024, Bondor Foods placed its first order for plant-based premixes for white fish and salmon patties, followed by Wyler Farm’s order for SH™-Beef premix for a new line of plant-based meat products. These initial revenues underscore the company’s successful transition from R&D to commercialization. Moreover, in a bid to attract new clients and partners, Steakholder Foods inaugurated a state-of-the-art Demonstration Center in Israel. The facility showcases live demonstrations of its MX200 and HD144 3D printers, highlighting their capabilities in real-time production of plant-based meat and seafood alternatives. This hands-on experience allows potential partners to witness the full production process, reinforcing the quality and versatility of Steakholder Foods’ offerings. Positioned for Potential Growth in Expanding Markets The PESG report places Steakholder Foods within the context of a rapidly expanding alternative protein market, projected to grow from $76.3 billion in 2023 to $423 billion by 2033. This growth is driven by consumer interest in sustainable and health-conscious food options. Additionally, the 3D food printing market is expected to surge, with estimates forecasting growth from USD 34.7 million in 2019 to USD 1,015.4 million by 2027, driven by advances in technology and consumer demand for innovative food solutions. The report highlights how Steakholder Foods’ advancements potentially align with these industry trends, positioning the company as a potential leader in sustainable food production. Its proprietary 3D printing technology and strategic partnerships are poised to capture a share of this growing demand, particularly as cost management initiatives and recurring revenues take effect. Outlook and Future Prospects With strategic partnerships maturing and a demonstration center enhancing its market presence, Steakholder Foods appears poised for potential revenue growth in the coming years. The company has noted that it is in advanced discussions for a high-impact international agreement expected to close by early 2025. This move could further bolster Steakholder Foods’ position as a leader in the alternative protein sector, which continues to gain momentum amid shifting consumer preferences and sustainability goals. Read the Full PESG Report: https://finance.yahoo.com/news/pesg-research-report-steakholder-foods-134500909.html *Please refer to the report’s full disclaimers and disclosures. This news alert may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Companies in emerging industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. *** This news alert is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. Global Markets News Network is a commercial digital brand compensated by the issuer (STKH) to provide coverage, sharing and syndication of news related to it and is thus subject to conflicts of interest. [ https://justpaste.it/bdh8v/pdf ]. Contact Details News Coverage globalmarkets.media@gmail.com

November 04, 2024 10:40 AM Eastern Standard Time

PathAI Launches PathExplore™ Fibrosis: An AI-Powered Pathology Breakthrough in Fibrosis, Collagen, and Fiber Quantification Directly from Whole Slide Images

PathAI

PathAI, a leader in AI-powered pathology solutions, is proud to introduce PathExplore™ Fibrosis 1 on our AISight® Translational Research platform, a one-of-a-kind AI tool designed to revolutionize fibrosis, collagen, and fiber quantification directly from whole-slide images (WSIs) of hematoxylin and eosin (H&E)-stained tissue. PathExplore™ Fibrosis offers an unprecedented ability to analyze morphology and spatial organization of fibrosis in the tumor microenvironment (TME) directly from routine pathology images at scale, providing new insights into tumor biology and therapeutic response. Fibrosis and collagen fibers are emerging as crucial biomarkers and drug targets due to their potential roles in cancer progression, metastasis, and immune response. Leveraging advanced machine learning techniques, PathExplore™ Fibrosis offers scalable, rapid analysis, making it a transformative tool in oncology translational research. PathAI’s solution facilitates this analysis directly from routine H&E pathology images from standard imaging platforms, democratizing access to key insights into tumor biology and therapeutic responses without the need of custom microscopy. "What began as internal research by our scientific team has evolved into a powerful tool for cancer researchers, enabling them to explore previously inaccessible aspects of tumor morphology," said Ben Glass, VP of Product and Translational Research at PathAI. "Fibrosis is increasingly recognized as a potentially important biomarker in cancer research. By making it possible to study this directly from routine H&E images, we’re providing researchers with the means to scale their understanding of disease biology, evaluate drug efficacy, and drive the development of new fibrosis-related therapies." “By combining the cell and tissue features provided by PathExplore™ 2 with collagen and fibrosis measurements from PathExplore™ Fibrosis, researchers now have access to an unprecedented multidimensional view of the TME,” said Eric Walk, M.D., FCAP, chief medical officer at PathAI. “From a single image, researchers can ask and answer new questions about the organization and morphology of fibrosis in the TME and how this inhibits or promotes cancer progression.” PathAI will be presenting novel findings utilizing PathExplore™ Fibrosis and the underlying technology at the upcoming Society of Immunotherapy of Cancer conference (SITC 2024) on November 6-11, 2024, in Houston, Texas. Be one of the first to access PathExplore™ Fibrosis by reaching out to us at bd@pathai.com or access our self-serve demo of PathExplore™ Fibrosis for hands-on experience here. SITC 2024 Abstracts #1378: Stromal collagen features from H&E-stained whole slide images are associated with lymphocyte infiltration and survival following checkpoint inhibition in patients with non-small cell lung cancer - in collaboration with Incendia Therapeutics #88: Machine learning-based collagen fiber quantification enables analysis of the pancreatic cancer tumor microenvironment directly from hematoxylin and eosin-stained whole slide images Footnotes 1: PathExplore™ Fibrosis is for research use only. Not for use in diagnostic procedures. 2: PathExplore™ is for research use only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples, with the potential to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

November 04, 2024 10:00 AM Eastern Standard Time

ENEOS brings Dazzling array of Booth Cars and New Products to SEMA 2024

ENEOS USA

ENEOS – Japan’s largest oil company and supplier of motor oil and transmission fluids to the majority of Asian vehicle manufacturers – will be located in booth #24133 in Central Hall at the annual SEMA Show in Las Vegas this week. The company supplies lubricating oil to Japanese and Asian manufacturers for factory fill around the world. It also provides the aftermarket with premium vehicle lubricants and is introducing a new line of EV/Hybrid fluids to assist with long term vehicle maintenance. The ENEOS booth will highlight its activities in the performance aftermarket, high-performance motorsports, and showcase its most advanced products. ENEOS display vehicles will be located throughout the show to capture the essence of ENEOS and its commitment to performance. ENEOS booth #24133 will feature a pair of high-profile vehicles, including a widebody 1971 Datsun 240Z and 1972 Toyota Celica. Both feature significant engine upgrades in addition to bodywork and chassis modifications that will appeal to performance enthusiasts. Additionally, ENEOS invited two vehicles from its annual Show Car Contest. A 1960 Renault Dauphine with a mid-engined VW VR6 engine conversion and 1100hp Mk4 Toyota Supra will both be displayed in Silver Lot V024 and V025. Details and photographs of all four vehicles are available below and in the News section on the ENEOS website here: eneos.us 1971 DATSUN 240Z The ENEOS booth #24133 will feature John Lau's “Devil Z” Datsun 240Z (S30), which was inspired by the anime manga series Wangan Midnight. The project is a collaboration between Lau and designer Jon Sibal – a SEMA veteran who designed the Datsun’s muscular widebody styling, also incorporating a Skillard custom front splitter and rear diffuser. The wider fenders allowed significantly bigger 17x11.5” front, 18x13” rear Work Meister M1 wheels with Toyo Proxes R888R tires. And with all that grip, the owner wanted to ensure the ENEOS-lubricated engine was up to the challenge, so he installed a Datsun 280ZX L28 bored to L30 with forged 87mm flat-top pistons, forged H-beam connecting rods, and a ported and polished P90 head. A Garrett G35-900 turbo was mounted on a Protuner ZTurbo manifold and downpipe, which forces air into a fabricated intake plenum with 47mm velocity stacks. Everything is controlled by a Haltech 2500 ECU programmed for E85 and providing traction control. Power is transmitted through a Nissan G37 six-speed transmission to a Ford Super 8 diff. Apex Engineered takes care of the major suspension components while Turbohoses crafted 340mm carbon-ceramic rotors to ensure the 240Z could stop efficiently. The car features a number of special emblems and easter eggs for visitors to find. These include billet pitchfork emblems on the exterior, a billet "Devil Z" oil cap under the hood, and personalized "Devil Z" Speedhut gauges inside. The car was assembled and painted by Supreme Auto Body, finished in Porsche PTS San Marino Blue Metallic. You’ll find the full spec on John’s “Devil Z” here: eneos.us 1972 TOYOTA CELICA Displayed alongside the 240Z in ENEOS booth #24133 is the first-generation Toyota Celica belonging to veteran racer, Formula DRIFT team manager and engineer, Stephan Papadakis. The barn find-turned-showpiece is Steph’s personal project, which has been chronicled on his popular social media channels, gaining hundreds of thousands of views. The 1972 Celica had been sitting for more than 20 years before Steph discovered it and began his off-season passion project to keep himself busy in between Formula DRIFT competition. The restoration included a bare metal bodywork overhaul, while the rare 18R-G four-cylinder, eight-valve, twin-cam engine was fully rebuilt and bored to 2.2 liters. Lubricated by ENEOS motor oil, it was converted to dual 44 Mikuni PHH side-draft carburetors and runs a Link ECU thanks to a full motorsport-spec wiring harness to enhance reliability. The engine produced 170hp close to its 8000rpm maximum, necessitating four-piston Wilwood big brakes front and rear. Steph significantly upgraded the suspension using JRZ dampers, Techno Toy Tuning front spindles and tension control rods, Annex Suspension caster and camber plates, four-link rear suspension and panhard bar. Steph was able to increase wheel and tire widths thanks to TRD-style fender flares, which were produced by Toy Garage along with a lip spoiler and rear wing to enhance the Celica’s road presence. The new fenders accommodate custom 15” three-piece wheels inspired by Tom’s heritage design. For anybody unfamiliar with Stephan Papadakis, he established an unbeatable reputation in Import Drag Racing, building the first front-wheel-drive, tube-chassis drag car. He then set records with the world’s fastest FWD and RWD Hondas, the first import driver to break 6sec, and the first to exceed 180mph. Steph was the 1999 SEMA Import Racer of the Year, 2000 NIRA Pro Comp Champion, 2001 NIRA Pro FWD Champion and IDRC Outlaw Class Champion. Joining Formula DRIFT in 2004, Papadakis Racing has won the PRO Championship in 2007 and 2008 with Tanner Foust driving, as well as 2015, 2021 and 2022 with Fredric Aasbo at the wheel of the 1200hp Toyota GR Supra. During the interim years, Papadakis cars have placed in the top three on numerous occasions, and Steph himself has been voted Formula Drift Team Manager of the Year several times. The Papadakis Racing Rockstar Energy / Toyota Racing GR Supra has been a regular podium contender using ENEOS motor and gear oils. Steph also uses ENEOS lubricants in all his personal projects, including the 1972 Toyota Celica. You’ll find the full spec on Steph’s Celica here: eneos.us 1960 RENAULT DAUPHINE As the winner of the 2024 ENEOS x Pit+Paddock Show Car Contest, 20-year Navy veteran Justin Cashmore was invited to display his car outdoors at SEMA. Having retired in 2019, he found time to “build stuff I like in the best way I can.” Stationed in Japan, Italy, Florida, and California, he found inspiration in automotive trends around the world, which he’s been able to translate into various builds, including his extraordinary Renault. Justin “pulled the car out of the desert” in 2017 and it became a Hot Wheels Legends Tour Finalist in 2019. It’s since been featured by Stanceworks, Autopia LA, Hoonigan and Avants before being chosen as our winner of the ENEOS x Pit+Paddock Show Car Contest. While the Renault wears its patina with pride, Justin’s Group 5 racing-inspired carbon fiber widebody, which extended the car 22” wider than stock, might distract you from its mid-engined layout. Sitting transversely behind the rear firewall is a 2.8L Volkswagen VR6 24v engine. Thanks to a United Motorsports tune, custom intake and exhaust, the VR6 develops 230hp. The power is transmitted by a VW 02M six-speed transmission with Peloquin limited-slip differential. The driver sits on the right side of the cockpit inside the custom chassis and is protected by a “bumper-to-bumper” rollcage. The chassis allowed Justin to build a custom pushrod/bellcrank suspension system, incorporating NASCAR take-off Schroeder sway bars. The custom fenders accommodate 17” Felgen Factory wheels with extra-wide Toyo R888R rubber and a Wilwood big brake kit. You’ll find the full spec on Justin’s remarkable Dauphine here: eneos.us 1995 TOYOTA SUPRA As a runner-up in the 2024 ENEOS x Pit+Paddock Show Car Contest, Leo Barrit was invited to display his Mk4 Supra JZA80 outdoors at SEMA. Based in San Diego, Leo has owned the car for the last 12 years and used his time productively to build it to an incredible specification. The highlights included a fully rebuilt 2JZ-GTE VVTi engine, which was stroked to 3.3L with a Brian Crower billet crank, 272 cams, gears, and a Ferrea valvetrain, featuring custom Hypertune cam covers, intake manifold, and fuel rail. Fitted with a custom twin-turbo setup, it uses BorgWarner EFR 7163 turbos, Turbosmart internal wastegates and blow-off valves, plus a custom manifold and hand-welded titanium piping. In this state, the engine develops more than 1100hp. The Supra features a unique Varis widebody kit that blends Ridox fenders with Solid and Joker aero pieces. It’s complemented by a Varis carbon fiber hood, canards and GT wing. Advan RZ-DF2 wheels were wrapped in Toyo Proxes R888R tires, while Brembo GT-S six-piston monobloc front calipers and four-piston rears were hard anodized black and provide optimal braking. The Supra has KW V3 coilovers with Stanceparts air cups to provide driveway clearance. The interior features period-correct Recaro Tomcat seats in yellow Kevlar fabric with matching rears. There’s also a matching steering wheel and Alcantara headliner, both with hand-stitched yellow accents. The sound system utilizes an Alpine ILX-507 head unit and Focal Flax EVO speakers plus a 10" JL subwoofer in a custom enclosure powered by a Focal amp. You’ll find the full spec on Leo’s mouthwatering Supra here: eneos.us TEAM ENEOS FORMULA DRIFT AUTOGRAPH SESSION WEDNESDAY NOVEMBER 6, 2PM ENEOS BOOTH #24133 IN CENTRAL HALL All 2024 SEMA Show attendees are invited to join Team ENEOS for an autograph session featuring its Formula DRIFT driver line-up including: ● Fredric Aasbo – three-time Formula DRIFT PRO Champion ● Dai Yoshihara – ENEOS ambassador and 2011 FD PRO Champion ● Odi Bakchis – Team Feal owner and 2024 FD PRO runner-up ● Simen Olsen – 2024 Team Feal FD PRO driver ● Faruk Kugay – FD PROSPEC driver and ENEOS ambassador ● Stephan Papadakis – owner and team manager of Papadakis Racing ● Hana Burton – ENEOS ambassador and driver ENEOS NEW PRODUCTS As a global R&D partner and technology innovator for many of the world’s automotive manufacturers, ENEOS constantly strives to provide applications for emerging transportation developments in line with global lubricant market trends. Making its debut at SEMA 2024 are four products in the ENEOS EV/Hybrid Line. The first is e-Axle Fluid, which was developed specifically for e-axles on electrified vehicles. This breakthrough formulation uses state-of-the-art ENEOS base oil technology to provide superior thermal and oxidation breakdown resistance compared to traditional ATF or Gear Oil. The low viscosity e-axle Fluid flows better at low temperatures than conventional oils, further improving energy efficiency. Additionally, ENEOS will introduce its new 50/50 Antifreeze/Coolant, which is a high-performance, extended life antifreeze with high heat transfer capability specifically designed for the cooling systems of EV, Hybrid, and Plug-in-Hybrid (PHEV) vehicles, as well as all types of diesels, gasoline and NG/LPG Internal Combustion Engines. The ENEOS Super Extended Life coolant offers its latest Hybrid Organic Acid Technology (HOAT) formulation. Designed for complete protection for all cooling systems and designed to cool electronic components with non-depleting corrosion inhibitors and maintenance-free protection. There are three formulations available, differentiated by Pink, Blue and Green coloring, with specific applications for vehicles from the major electric vehicle OEMs and a wider range of hybrid vehicles. More information on the ENEOS EV/Hybrid Line is available at eneos.us EDITOR’S NOTE Images of the ENEOS booth vehicles are available here: dropbox.com/scl/fo/j3hylpzkvz2bg0immz9b9/ACIADzQx0ctt0JdlBe9puUU?rlkey=5jr89zd9pvz2o05xy3wu5362f&dl=0 You’ll find this release, complete with full tech spec on all four cars at eneos.us ABOUT ENEOS MOTOR OIL Established in 1888 and headquartered in Tokyo, ENEOS is Japan’s largest oil company, with manufacturing and sales facilities throughout the world. With a unique position in its home market, ENEOS has worked with Asia’s automakers and leading race teams for decades, creating advanced lubricants with their vehicle engineers to provide optimum fuel economy with maximum power and long-term protection. ENEOS also recently announced availability of a new 0W-8 motor oil for future vehicle applications including the latest hybrid technology. For more information, please visit eneos.us Contact Details Greg Emmerson greg@theidagency.com Company Website https://www.eneos.us

November 04, 2024 06:07 AM Pacific Standard Time

Image

1 ... 15 16 17 18 19 ... 3771

Back

Why News Direct

For Public Relations For Investor Relations Testimonials

About us Features News Hub

Resources

Press Blog

Why News Direct For Public Relations For Investor Relations Testimonials

What We Offer Collaborative Content Studio Advanced News Release Capability Standalone Multimedia Distribution Industry-Leading Security Unsurpassed Global Reach Actionable Analytics Synergistic PR Solutions

Pricing About us News Hub

Resources Blog Press